Clinical implications of Comprehensive Genomic Profiling on liquid biopsy for lung cancer patients


With rapidly growing number, complexity, and diversity of relevant cancer biomarkers, NGS-based comprehensive genomic profiling (CGP) has become a valuable tool in uncovering gene mutations and genomic alterations, providing critical information for therapy guidance. Liquid biopsy with ctDNA characterisation allows to match patients with appropriate therapies and gets essential when conventional tissue collection is infeasible. 

In this webinar, Dr Federico Cappuzzo will speak about clinical implications of liquid biopsy-based CGP for lung cancer patients, discussing current clinical evidence and sharing his vision on future applications.

Learning Objectives:

  • Clinical utility of performing liquid biopsy in lung cancer patients: current status, challenges and perspectives
  • Growing evidence of implementing CGP in liquid biopsy
  • Value of liquid biopsy-based CGP of ctDNA in improving patient outcome

Dr. Federico Cappuzzo

Director of Medical Oncology , National Cancer Institute Regina Elena, Rome, Italy

Dr. Federico Cappuzzo has been the Director of Medical Oncology at the National Cancer Institute Regina Elena in Rome. In November 1992, he graduated, summa cum laude, in Medicine and surgery at the Palermo University and in November 1996, yielded a Degree summa cum laude in Medical Oncology at Milan University, followed by the ESMO (European Society for Medical Oncology) certification in Medical Oncology in 1997. From 1997 to 1999 he was recipient of an ESMO Fellowship on Gene Therapy of Lung Cancer at Institut Gustave Roussy in Villejuif (Paris).

Followed by attendance from April 2000 to September 2000 at the thoracic oncology unit at Medical University of South Carolina in Charleston (USA). For six years, from November 2000 to 2006, he was assistant professor at Ospedale Bellaria in Bologna and from November 2006 to January 2010 he was assistant professor in Medical Oncology at Istituto Clinico Humanitas IRCCS in Rozzano (Milano), which was followed in January 2004 to November 2004 as visiting professor in Medical Oncology at University of Colorado in Denver (USA). From January 2010 to April 2016 he was the Director of Medical Oncology Department at the Istituto Toscano Tumori-Ospedale Civile in Livorno. From April 2016 to September 2020 he was Director of Oncology and Hematology Department at AUSL Romagna in Ravenna.
Dr. Cappuzzo is a member of the Italian Association in Medical Oncology (AIOM), European Society for Medical Oncology (ESMO), American Society Clinical Oncology (ASCO) and International Association for the Study of Lung Cancer (IASCL) and since 2006 as a Member of the editorial board of Lung Cancer.

From 2013 to 2017 he was the Chairman of the Educational Committee of IASLC. He is the author of more than 250 papers in peer-review journals, mainly in translational research in lung cancer.